No Data
Top Gap Ups and Downs on Tuesday: SNY, NVS, C and More
DA Davidson Downgrades Novartis to Neutral From Buy, Price Target Is $120
Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development, Production, Commercialization
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Novartis (NVS.US) has received clinical approval in China for a Class 1 new drug for radioactive cancer therapy.
On March 3rd, the CDE official website announced that Novartis (NVS.US) has received approval for clinical trials for the Class 1 new drug [225Ac]Ac-PSMA-617 injection, intended to treat PSMA-positive metastatic castration-resistant prostate cancer that progresses during or after [177Lu]Lu-PSMA targeted therapy.
Novartis Gets EU Positive Recommendation for Its Kidney Disease Treatment
